Research guide / Semaglutide
What is Semaglutide? A Complete Research Guide.
Updated August 2026 · 12 minute read
Semaglutide is a long-acting peptide that activates the GLP-1 receptor — the most extensively studied incretin target in modern metabolic research. This guide separates what peer-reviewed studies show from what registries record and what regulators have actually approved.
01 / Overview
What is semaglutide?
Semaglutide, developed by Novo Nordisk, is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist — a peptide engineered with a half-life of approximately one week, allowing once-weekly dosing in clinical studies.[1]
It is a selective single-receptor agonist: it activates the GLP-1 receptor only. That distinguishes it from dual agonists such as tirzepatide (GIP + GLP-1) and investigational triple agonists such as retatrutide (GIP + GLP-1 + glucagon).
Semaglutide has one of the largest evidence bases of any incretin-based compound, spanning type 2 diabetes (the SUSTAIN programme), obesity (the STEP programme), and cardiovascular outcomes (SUSTAIN-6 and SELECT). It has completed regulatory review in multiple jurisdictions and is approved under brand names including Ozempic and Wegovy.
02 / Mechanism
How does semaglutide work?
Semaglutide is designed to bind to and activate the GLP-1 receptor, a receptor involved in nutrient sensing and glucose regulation. It is a single peptide analogue of the human GLP-1 hormone, modified to resist breakdown and extend its duration of action.[1], [3]
| Pathway | Normal signalling role | Research relevance |
|---|---|---|
| GLP-1 receptor | Participates in glucose-dependent insulin signalling, satiety signalling, and gastric function. | The sole target of semaglutide and the most extensively studied incretin receptor in metabolic research. |
| GIP receptor | Participates in nutrient-responsive, glucose-dependent insulin signalling. | Semaglutide does not target this receptor — that is the key pharmacological difference from the dual agonist tirzepatide. |
| Glucagon receptor | Participates in hepatic glucose regulation and energy metabolism. | Semaglutide does not target this receptor — that is the key pharmacological difference from the investigational triple agonist retatrutide. |
The working model is that GLP-1 receptor activity influences glucose-dependent insulin secretion, satiety signalling, and gastric emptying. These mechanisms are studied in controlled settings; how they combine to produce the outcomes seen in any individual cannot be predicted from trial averages and should not be treated as settled.
03 / Published evidence
Peer-reviewed findings
In the 68-week STEP 1 Phase 3 trial, 1,961 adults with obesity or overweight (without diabetes) were randomised to once-weekly semaglutide 2.4 mg or placebo, plus lifestyle intervention. Mean body-weight change at week 68 was −14.9% with semaglutide versus −2.4% with placebo, and 86.4% of semaglutide participants lost at least 5% of body weight versus 31.5% with placebo. These are group averages from a controlled trial, not expected individual results.[1]
In the SELECT trial, 17,604 patients aged 45 or older with preexisting cardiovascular disease and overweight or obesity — but without diabetes — were randomised to semaglutide 2.4 mg or placebo. Over a mean follow-up of 39.8 months, the primary composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke occurred in 6.5% of the semaglutide group versus 8.0% with placebo (hazard ratio 0.80).[2]
In the earlier SUSTAIN-6 trial, 3,297 patients with type 2 diabetes at high cardiovascular risk were randomised to once-weekly semaglutide (0.5 or 1.0 mg) or placebo for 104 weeks. The primary composite outcome occurred in 6.6% of the semaglutide group versus 8.9% with placebo (hazard ratio 0.74), establishing cardiovascular noninferiority; rates of new or worsening nephropathy were lower, while retinopathy complications were significantly higher (hazard ratio 1.76).[3]
04 / Trial registry
Registered clinical programme
A registry record shows what a study was designed to test and its reported recruitment status. It does not by itself establish efficacy, safety, or approval.
| Programme | Trial ID | Population | Registry status |
|---|---|---|---|
| STEP 1 | NCT03548935 | Obesity or overweight, without type 2 diabetes | Completed · 1,961 participants |
| SELECT | NCT03574597 | Cardiovascular disease with overweight or obesity, without diabetes | Completed · 17,604 participants |
| SUSTAIN-6 | NCT01720446 | Type 2 diabetes at high cardiovascular risk | Completed · 3,297 participants |
Statuses and enrolment figures reflect the original ClinicalTrials.gov records reviewed for this August 2026 update. Registry records can change.[4], [5], [6]
Afiya Labs lists reference materials for laboratory research. Catalogue entries are not medicine listings and are not presented as suitable for human use.
05 / Safety evidence
What safety findings have trials reported?
In STEP 1, the most common adverse events with semaglutide 2.4 mg were gastrointestinal — primarily nausea and diarrhea — typically mild to moderate and transient. More participants discontinued due to adverse events in the semaglutide group than with placebo.[1]
In SELECT, adverse events leading to permanent discontinuation occurred in 16.6% of the semaglutide group versus 8.2% with placebo. In SUSTAIN-6, retinopathy complications were significantly higher with semaglutide (hazard ratio 1.76), a finding the approved prescribing information addresses. Approved products carry a boxed warning about thyroid C-cell tumours seen in rodent studies.[2], [3]
Controlled trials cannot answer every long-term safety question. Findings depend on the studied population, follow-up period, and dose-escalation design. Anyone considering an approved semaglutide medicine should rely on its official prescribing information and a licensed clinician, not a research summary.
06 / Regulators
Approval status in the US, Europe, and UAE
United States
Semaglutide is FDA-approved under two brand names: Ozempic (5 December 2017) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, and Wegovy (4 June 2021) for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. Separately, the FDA has published concerns about unapproved and compounded GLP-1 products, which are not the same as the approved medicines.[7], [8], [9]
European Union
Semaglutide is authorised in the EU under the brand names Ozempic and Wegovy, following positive EMA assessments. A marketing authorisation applies only to the assessed product, its approved indications, and its official labelling — not to other materials sold under the same molecule name.
United Arab Emirates
The Emirates Drug Establishment maintains the UAE's public registered medical product directory. We did not rely on a directory search to infer approval, non-approval, legality, availability, or permission for use of any specific product; those questions require confirmation from the EDE. Approved medicines in the UAE are dispensed through licensed channels.[10]
07 / Quick answers
Frequently asked questions
Is semaglutide an approved medicine?
Yes, in several jurisdictions under specific brand names and indications — Ozempic and Wegovy in the US and the EU. Approval applies to those assessed products only, through licensed prescribers and pharmacies; it does not extend to research or compounded materials.
Why is it called a GLP-1 receptor agonist?
It activates the glucagon-like peptide-1 receptor, mimicking a natural incretin hormone involved in glucose regulation and appetite signalling. The term describes its pharmacology, not a dosing or usage recommendation.
How does semaglutide differ from tirzepatide?
Semaglutide is a selective GLP-1 receptor agonist, while tirzepatide also activates the GIP receptor. In the head-to-head SURPASS-2 trial, tirzepatide produced greater average HbA1c and weight reductions than semaglutide 1 mg over 40 weeks.
How does it differ from retatrutide?
Retatrutide is an investigational triple agonist that adds GIP and glucagon receptor activity to GLP-1. Unlike semaglutide, retatrutide has not completed regulatory review and is not an approved medicine.
What side effects were seen in trials?
Gastrointestinal events — nausea, diarrhea, and vomiting — were the most common in the cited trials, mostly mild to moderate and concentrated during dose escalation. Approved products carry a boxed warning about rodent thyroid C-cell tumour findings; full safety information lives in the official prescribing information.
What does the UAE directory show?
It is a public register of medical products. This guide does not turn a directory search result — or the absence of one — into a claim about approval, legality, or permitted use. The EDE is the appropriate authority for a current determination.
08 / Sources
References and original records
- 1Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). The New England Journal of Medicine. 2021 · DOI 10.1056/NEJMoa2032183 · NCT03548935.
- 2Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). The New England Journal of Medicine. 2023 · DOI 10.1056/NEJMoa2307563 · NCT03574597.
- 3Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). The New England Journal of Medicine. 2016 · DOI 10.1056/NEJMoa1607141 · NCT01720446.
- 4STEP 1 trial record. ClinicalTrials.gov. NCT03548935.
- 5SELECT trial record. ClinicalTrials.gov. NCT03574597.
- 6SUSTAIN-6 trial record. ClinicalTrials.gov. NCT01720446.
- 7Ozempic (semaglutide) application overview, NDA 209637. U.S. Food and Drug Administration — Drugs@FDA. Approval date 5 December 2017 · Official regulatory record.
- 8Wegovy (semaglutide) injection — NDA 215256 approval letter. U.S. Food and Drug Administration. 4 June 2021 · Official FDA approval letter for chronic weight management.
- 9FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration. Official regulatory statement on unapproved and compounded products.
- 10Registered medical product directory. UAE Emirates Drug Establishment. Official public directory · checked August 2026.